Assessing cancer risk in the anterior part of the prostate using micro-ultrasound: validation of a novel distinct protocol.
Micro-ultrasound
Prostate biopsy
Prostate cancer
Transitional zone
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
19
06
2023
accepted:
21
08
2023
medline:
9
11
2023
pubmed:
15
9
2023
entrez:
15
9
2023
Statut:
ppublish
Résumé
To develop and validate a micro-ultrasound risk score that predicts the likelihood of significant prostate cancer in the anterior zone. Patients were enrolled from three expert institutions familiar with micro-ultrasound. The study was conducted in two phases. First, the PRI-MUS anterior score was developed by assessing selected prostate videos from patients who subsequently underwent radical prostatectomy. Second, seven urology readers with varying levels of experience in micro-ultrasound examination evaluated prostate loops according to the PRI-MUS anterior score. Each reader watched the videos and recorded the likelihood of the presence of significant cancer in the anterior part of the prostate in a three-point scale. The coherence among the readers was calculated using the Fleiss kappa and the Cronbach alpha. A total of 102 selected prostate scans were used to develop the risk assessment for anterior zone cancer in the prostate. The score comprised three categories: likely, equivocal, and unlikely. The median (IQR) sensitivity, specificity, positive predictive value, and negative predictive value for the seven readers were 72% (68-84), 68% (64-84), 75% (72-81), and 73% (71-80), respectively. The mean SD ROC AUC was 0.75 ± 2%, while the Fleiss kappa and the Cronbach alpha were 0.179 and 0.56, respectively. Micro-ultrasound can detect cancerous lesions in the anterior part of the prostate. When combined with the PRI-MUS protocol to assess the peripheral part, it enables an assessment of the entire prostate gland. Pending external validation, the PRI-MUS anterior score developed in this study might be implemented in clinical practice.
Identifiants
pubmed: 37712968
doi: 10.1007/s00345-023-04591-w
pii: 10.1007/s00345-023-04591-w
pmc: PMC10632243
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3325-3331Informations de copyright
© 2023. The Author(s).
Références
Urol Oncol. 2014 Jan;32(1):34.e27-32
pubmed: 23558161
J Urol. 2019 Dec;202(6):1166-1173
pubmed: 31246546
Eur Urol Oncol. 2019 May;2(3):329-332
pubmed: 31200848
J Urol. 2016 Aug;196(2):562-9
pubmed: 26791931
Lancet Oncol. 2022 Mar;23(3):428-438
pubmed: 35240084
Lancet Oncol. 2019 Jan;20(1):100-109
pubmed: 30470502
Contemp Clin Trials. 2022 Jan;112:106618
pubmed: 34728381
Radiology. 2022 Nov;305(2):390-398
pubmed: 35852425
N Engl J Med. 2018 May 10;378(19):1767-1777
pubmed: 29552975
Eur Urol. 2019 Jul;76(1):43-51
pubmed: 30824296
Abdom Radiol (NY). 2017 Jan;42(1):278-289
pubmed: 27522352
Prog Urol. 2022 Jun;32(6S1):6S26-6S32
pubmed: 36719643
BJU Int. 2022 May;129(5):648-654
pubmed: 34773679
World J Urol. 2015 Nov;33(11):1651-9
pubmed: 25761736
Am J Surg Pathol. 2020 Aug;44(8):e87-e99
pubmed: 32459716
PLoS One. 2023 Jan 18;18(1):e0280262
pubmed: 36652429
BJU Int. 2000 Jul;86 Suppl 1:123-34
pubmed: 10961282
J Urol. 2021 May;205(5):1254-1262
pubmed: 33577367
Can Urol Assoc J. 2021 Jan;15(1):E11-E16
pubmed: 32701437